Gilead Sciences has signed a definitive agreement for the acquisition of the complete outstanding share capital of MiroBio in a deal valued at nearly $405m in cash, subject to necessary adjustments.

With the acquisition, Gilead will gain access to the discovery platform and complete line of immune inhibitory receptor agonists of MiroBio. 

The scientific approach of MiroBio for immune balance restoration to treat autoimmune diseases complements the inflammation research and development works of Gilead.

MB272, the lead investigational antibody of MiroBio, is a selective immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) agonist. 

It is currently in Phase I clinical trials, with the first subject dosed recently. 

The antibody acts on T, B and dendritic cells to hinder or dull activation and control an inflammatory immune response.

MiroBio’s REceptor Selection and Targeting to Reinstate immune Equilibrium (I-ReSToRE) platform can potentially be utilised for developing agonist antibodies that act on immune inhibitory receptors. 

The platform aids in detecting and developing therapies that use inhibitory signalling networks to restore immune homeostasis in patients. 

Gilead plans to progress further agonists obtained from the I-ReSToRE platform, including MB151, a PD-1 agonist, as well as various other early-stage programmes that are not disclosed so far in the future.

The deal will close following the waiting period expiry or termination under the Hart-Scott-Rodino Antitrust Improvements Act, as well as various other necessary conditions.

Gilead Sciences Research executive vice-president Flavius Martin said: “The team at MiroBio has spearheaded foundational research for agonist antibodies following a rigorous scientific approach.

“We believe that MiroBio’s unique platform technology has the potential to produce best-in-class agonist antibodies targeting immune inhibitory receptors.”

Prior to this development, the company reported a 1% revenue rise to $6.3bn in Q2 2022.